GLP-1 Receptor Agonists Reduce Mortality in Type 2 Diabetes Patients
Research suggests that mortality rates are lower in people with type 2 diabetes who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to those who do not.
A study by academics from Emory University in Atlanta found that GLP-1 RAs significantly protect people with type 2 diabetes and obstructive sleep apnoea (OSA) from mortality.
- The study examined the health outcomes of 1,799,261 adults with type 2 diabetes.
- Participants were grouped into four categories:
- Without OSA and prescribed metformin
- Without OSA and prescribed metformin and GLP-1 RAs
- With OSA and prescribed metformin
- With OSA and prescribed metformin and GLP-1 RAs
The results showed that participants prescribed GLP-1 RAs had reduced one-year mortality compared to those only prescribed metformin.
No direct quote available in the text.
Author's summary: GLP-1 RAs reduce mortality in type 2 diabetes patients.
More News
- Broad Survival Benefit from MATTERHORN Trial Highlights New Approach to Biomarker Use | Applied Clinical Trials Online
- Hong Kong Tennis Open: last China players exit as top seed Bencic progresses
- “He Left His Mark on the Hands of Time”
- Selling Sunset: Has Nicole been fired? Fans left cringing at ‘horrendous’ remark
- Dutch election: D66 and PVV neck and neck with smallest difference ever
- STORM WATCH: Strong wind gusts up to 50 mph, heavy rain passes across NJ today
- US passport support in Apple Wallet is a hugely important step
- Mark Carney needs to come clean on climate